Welcome to Medivizor!

You're browsing our sample library. Feel free to continue browsing. You can also sign up for free to receive medical information specific to your situation.

Posted by on Jun 27, 2018 in Multiple Myeloma | 0 comments

In a nutshell

This study examined the use of bisphosphonate treatment for bone protection in patients with multiple myeloma. This study concluded that many patients do not receive adequate bone protection.

Some background

In multiple myeloma, bones are commonly affected, leading to bone destruction. Bisphosphonates are a group of drugs that prevent bone loss. They are the standard recommendation for treating bone disease in patients with multiple myeloma. Studies have shown that bisphosphonates reduce the occurrence of bone problems like fractures. However, it is not clear as to how long bisphosphonates should be given and when the dose should be reduced. This is important as one side effect of bisphosphonates is that they affect kidney function.

Methods & findings

11,112 patients with multiple myeloma were included. Patients were followed for an average 818 days. 63% of patients received bisphosphonate during the follow-up period. 6180 patients received zoledronic acid (Zometa) only and 489 received pamidronate (Aredia) only.

There was an average of 106 days from the day of diagnosis to the day of first bisphosphonate treatment. The average duration of bisphosphonate treatment was 498 days. Of patients who started bisphosphonates, 58% started it within the first year of diagnosis. The average number of doses given in the first year was 6.8.

82% of patients who received bisphosphonate either stopped or changed dose at least once during the study period. Of these patients, 62% stopped treatment. The average duration of treatment for patients who stopped treatment was 318 days.

46.3% of patients had impaired kidney function. Patients with worse kidney function at the start of the study were less likely to receive bisphosphonates. Patients with worse kidney function were more likely to have a delay in receiving bisphosphonate treatment than patients with better kidney function.

The bottom line

The authors concluded that patients with multiple myeloma may not receive optimal treatment for bone disease, especially those with impaired kidney function.

What’s next?

Talk to your doctor about your need for bone protection therapy.

Published By :

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer

Date :

Mar 07, 2018

Original Title :

Patterns of bisphosphonate treatment among patients with multiple myeloma treated at oncology clinics across the USA: observations from real-world data.

click here to get personalized updates